Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Czechia / NCT06820905
Starting soon Observational

Hyperinflammation and Hyperferritinemia in Critically Ill Patients

NCT06820905 · tracked via the Priya Life Science Czechia tracker
Sponsor
Charles University, Czech Republic
Phase
Observational
Started
2025-02-20
Last updated
2025-02-11

Condition(s) studied

Critical IllnessSepsisHyperferritinemiaHyperinflammatory Syndrome

Study summary

Analysing trajectory of critically ill patients with signs of hyperinflammation

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * critically ill patients * admission between 01.01.2020 and 31.12.2024 (5yrs) Exclusion Criteria: * none

Primary outcome measure(s)

  • hyperferritinemia — 2025
    trajectory of critically ill patients with significant hyperferritinemia and with regard to its dynamics; ferritin value cutt-off

Trial sites (1)

FacilityCityRegionStatus
Faculty of Medicine and Teaching Hospital, Charles University Pilsen Czech Republic

More Charles University, Czech Republic trials in Czechia

Immune Homeostasis in Sepsis and Septic Shock Recruiting
Exercise-Based Strategies for Chronic Back Pain Starting soon
Detection of Muscle Quality in Children - Protocol for a Validation Study Starting soon
PAN-ICIS Study: ICIS for Early Detection of Infectious Complications in Pancreatic Surgery Active, not recruiting
Single-center Evaluation of Human Milk Quantity and Quality Over Five Years Recruiting

Other trials for the same condition

Immune Homeostasis in Sepsis and Septic Shock Recruiting
Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients Recruiting
Reduction of Muscle Catabolism Through Brain Activation in Burn Patients Starting soon
Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure Recruiting
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06820905 on ClinicalTrials.gov ↗ ← All trials in Czechia